HLVX · Insider Trading
HilleVax, Inc. Common Stock
Every open-market purchase and sale reported by HLVX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-09-17 | Gary Dubin | Director | U | −17,199 | — |
| 2025-09-17 | Jaime Sepulveda | Director | U | −59,224 | — |
| 2025-09-17 | Shane Maltbie | Chief Financial Officer | U | −83,738 | — |
| 2025-09-17 | Jeryl L Hilleman | Director | U | −59,224 | — |
| 2025-09-17 | Shelley Chu | Director | U | −17,199 | — |
| 2025-09-17 | Aditya Kohli | Director | U | −698,171 | — |
| 2025-09-17 | Julie L. Gerberding | Director | U | −59,224 | — |
| 2025-09-17 | Nanette Cocero | Director | U | −17,199 | — |
| 2025-09-17 | Robert Hershberg | President and CEO | U | −1,101,498 | — |
| 2025-09-17 | FHMLS X, L.L.C. | 10%+ Owner | U | −42,762,680 | −$83.39M |
| 2025-06-25 | Shelley Chu | Director | A | +17,199 | — |
| 2025-06-25 | Jeryl L Hilleman | Director | A | +17,199 | — |
| 2025-06-25 | Julie L. Gerberding | Director | A | +17,199 | — |
| 2025-06-25 | Nanette Cocero | Director | A | +17,199 | — |
| 2025-06-25 | Patrick J Heron | Director | A | +17,199 | — |
| 2025-06-25 | Jaime Sepulveda | Director | A | +17,199 | — |
| 2025-06-25 | Aditya Kohli | Director | A | +17,199 | — |
| 2025-06-25 | Gary Dubin | Director | A | +17,199 | — |
| 2025-04-30 | Shelley Chu | Director | A | +22,500 deriv. | — |
| 2025-04-30 | Julie L. Gerberding | Director | A | +22,500 deriv. | — |
| 2025-04-30 | Patrick J Heron | Director | A | +22,500 deriv. | — |
| 2025-04-30 | Nanette Cocero | Director | A | +22,500 deriv. | — |
| 2025-04-30 | Jaime Sepulveda | Director | A | +22,500 deriv. | — |
| 2025-04-30 | Jeryl L Hilleman | Director | A | +22,500 deriv. | — |
| 2025-02-12 | Shane Maltbie | Chief Financial Officer | Sell | −8,291 | −$15.12K |
| 2025-02-12 | Robert Hershberg | See Remarks | Sell | −26,535 | −$48.66K |
| 2024-05-31 | FHMLS X, L.L.C. | 10%+ Owner | — | — | — |
| 2024-05-22 | Aditya Kohli | Director | Sell | −18,000 | −$266.29K |
| 2024-05-03 | Aditya Kohli | Director | Sell | −6,898 | −$96.77K |
| 2024-04-08 | James N Topper | 10%+ Owner | Buy | +44,250 | +$641.62K |
| 2024-04-05 | Aditya Kohli | Director | Sell | −18,000 | −$264.47K |
| 2024-04-01 | Sean McLoughlin | Chief Operating Officer | Buy | +1,250 | +$21.23K |
| 2024-03-20 | Aditya Kohli | Director | Sell | −18,000 | −$985.54M |
| 2024-03-08 | Aditya Kohli | Director | Sell | −18,000 | −$335.87K |
| 2024-02-22 | Aditya Kohli | Director | Sell | −18,000 | −$269.08K |
| 2024-02-14 | Aditya Kohli | Director | Sell | −6,000 | −$91.92K |
| 2024-02-12 | Robert Hershberg | See Remarks | MIXED | +162,605 | −$173.16K |
| 2024-02-12 | Aditya Kohli | Director | MIXED | +46,032 | −$132.38K |
| 2024-02-12 | Shane Maltbie | Chief Financial Officer | MIXED | +43,946 | −$53.40K |
| 2024-02-12 | Astrid Borkowski | Chief Medical Officer | MIXED | +49,699 | −$58.73K |
| 2024-02-02 | Sean McLoughlin | Chief Operating Officer | A | +250,000 deriv. | — |
| 2023-12-18 | Astrid Borkowski | Chief Medical Officer | Sell | −10,000 | −$155.00K |
| 2023-12-05 | Astrid Borkowski | Chief Medical Officer | Sell | −20,000 | −$287.00K |
| 2023-11-20 | Astrid Borkowski | Chief Medical Officer | Sell | −10,000 | −$140.00K |
| 2023-11-13 | Astrid Borkowski | Chief Medical Officer | Sell | −5,000 | −$65.00K |
| 2023-06-23 | Astrid Borkowski | Chief Medical Officer | D | −10,000 | −$161.10K |
| 2023-06-09 | Shelley Chu | Director | A | +22,500 deriv. | — |
| 2023-06-09 | Jeryl L Hilleman | Director | A | +22,500 deriv. | — |
| 2023-06-09 | Nanette Cocero | Director | A | +11,000 deriv. | — |
| 2023-06-09 | Jaime Sepulveda | Director | A | +22,500 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Patrick J Heron | Director | 8,552,536 | $17.87M |
| FHMLS X, L.L.C. | 10%+ Owner | 8,535,337 | $17.84M |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the HLVX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.